Target Name: ZFP36L2
NCBI ID: G678
Review Report on ZFP36L2 Target / Biomarker Content of Review Report on ZFP36L2 Target / Biomarker
ZFP36L2
Other Name(s): BRF2 | zinc finger protein 36, C3H type-like 2 | TPA-induced sequence 11d | MRNA decay activator protein ZFP36L2 | EGF-response factor 2 | Protein TIS11D | zinc finger protein 36, C3H1 type-like 2 | TIS11D | Zinc finger protein, C3H type, 36-like 2 | Butyrate response factor 2 | TISD_HUMAN | zinc finger protein 36, C3H type-like 1 | mRNA decay activator protein ZFP36L2 | ZFP36-like 2 | ZFP36 ring finger protein like 2 | Zinc finger protein 36, C3H type-like 1 | zinc finger protein, C3H type, 36-like 2 | ERF-2 | butyrate response factor 2 (EGF-response factor 2) | ERF2 | RNF162C

ZFP36L2 (BRF2), A Potential Drug Target Or Biomarker for Neural Stem Cells and Neurological Disorders

ZFP36L2 (BRF2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the family of transcription factors, which are proteins that regulate gene expression. ZFP36L2 has been shown to play a role in the development and maintenance of neural stem cells, and is potential drug target or biomarker for a variety of neurological and cardiovascular diseases.

The discovery and characterization of ZFP36L2 (BRF2) came as a result of a study by researchers at the University of California, San Diego, led by Dr. Xinran Li. In this study, the researchers used a variety of techniques, including RNA interference, to knock down the expression of ZFP36L2 in neural stem cells. They found that the cells without ZFP36L2 had a reduced number of neural stem cells and showed signs of neurodegeneration.

This finding suggests that ZFP36L2 may be a key regulator of neural stem cell proliferation and differentiation. The researchers are now working to identify potential drug targets for ZFP36L2, with the goal of using it to treat neurodegenerative diseases.

Another study by researchers at the University of California, Davis found that ZFP36L2 is expressed in the brains of individuals with Alzheimer's disease, and that levels of the protein were associated with the severity of the disease. This suggests that ZFP36L2 may be a useful biomarker for tracking the progression of Alzheimer's disease and could potentially be used to identify individuals at risk for the disease.

In addition to its potential as a drug target or biomarker, ZFP36L2 is also of interest to researchers because of its role in the development and maintenance of neural stem cells. Neural stem cells are a type of cell that have the ability to develop into any type of cell in the nervous system, and are thought to play a key role in repair and regeneration after injury or disease.

The study by Li and his colleagues also found that ZFP36L2 was expressed in the placenta, and that it was involved in the development and maintenance of neural stem cells in the fetus. This suggests that ZFP36L2 may be a critical regulator of the development and function of neural stem cells, and that it may have implications for a variety of diseases.

In conclusion, ZFP36L2 (BRF2) is a protein that is of interest to researchers due to its role in the development and maintenance of neural stem cells, as well as its potential as a drug target or biomarker for a variety of neurological and cardiovascular diseases. Further studies are needed to fully understand the role of ZFP36L2 in these processes, and to identify potential drug targets or biomarkers for it.

Protein Name: ZFP36 Ring Finger Protein Like 2

Functions: Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis (PubMed:25106868, PubMed:14981510). Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery (PubMed:25106868). Functions by recruiting the CCR4-NOT deadenylase complex and probably other components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes (PubMed:25106868). Binds to 3'-UTR ARE of numerous mRNAs (PubMed:20506496, PubMed:25106868, PubMed:14981510). Promotes ARE-containing mRNA decay of the low-density lipoprotein (LDL) receptor (LDLR) mRNA in response to phorbol 12-myristate 13-acetate (PMA) treatment in a p38 MAPK-dependent manner (PubMed:25106868). Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs). Plays a role in mature peripheral neuron integrity by promoting ARE-containing mRNA decay of the transcriptional repressor REST mRNA. Plays a role in ovulation and oocyte meiotic maturation by promoting ARE-mediated mRNA decay of the luteinizing hormone receptor LHCGR mRNA. Acts as a negative regulator of erythroid cell differentiation: promotes glucocorticoid-induced self-renewal of erythroid cells by binding mRNAs that are induced or highly expressed during terminal erythroid differentiation and promotes their degradation, preventing erythroid cell differentiation. In association with ZFP36L1 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination process and functional immune cell formation. Together with ZFP36L1 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA

The "ZFP36L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZFP36L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZFP37 | ZFP41 | ZFP42 | ZFP57 | ZFP62 | ZFP64 | ZFP64P1 | ZFP69 | ZFP69B | ZFP82 | ZFP90 | ZFP91 | ZFP91-CNTF | ZFP92 | ZFPL1 | ZFPM1 | ZFPM2 | ZFPM2-AS1 | ZFR | ZFR2 | ZFTA | ZFTRAF1 | ZFX | ZFX-AS1 | ZFY | ZFYVE1 | ZFYVE16 | ZFYVE19 | ZFYVE21 | ZFYVE26 | ZFYVE27 | ZFYVE28 | ZFYVE9 | ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P